This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT00488241
First received: June 19, 2007
Last updated: February 25, 2014
Last verified: February 2014
June 19, 2007
February 25, 2014
June 2007
September 2007   (Final data collection date for primary outcome measure)
Hand eczema severity index (HECSI)at the end of study [ Time Frame: End of study compared to baseline ]
Same as current
Complete list of historical versions of study NCT00488241 on ClinicalTrials.gov Archive Site
  • Investigator's Global Assessment [ Time Frame: End of study compared to baseline ]
  • Patients assessment of itch [ Time Frame: End of study compared to baseline ]
  • Hand surface area [ Time Frame: End of study compared to baseline ]
  • Clinical signs of hand eczema [ Time Frame: End of study compared to baseline ]
Same as current
Not Provided
Not Provided
 
Multicenter Clinical Study to Examine the Efficacy and Safety of Zarzenda in Patients With Hand Eczema
A Multicenter, Open Uncontrolled Clinical Study to Examine the Efficacy and Safety of Zarzenda in the Management of Hand Eczema
To show efficacy of Zarzenda in the treatment of hand eczema
The objective of the study is to demonstrate efficacy and safety of Zarzenda (a medical device) in the management of hand eczema.
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hand Eczema
Device: Zarzenda
Topically applied daily for 2 weeks
Active Comparator: 1
Topically applied daily for 2 weeks
Intervention: Device: Zarzenda
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
40
September 2007
September 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Mild to moderate hand eczema for at least 3 months
  • At least 4 weeks have passed since use of systemic treatment for eczema
  • At least 4 weeks have passed since any vaccination
  • At least 1 week has passed since last topic treatment on hands with corticosteroids
  • Agree to use adequate contraceptive method if of childbearing potential
  • Willingness to avoid excessive exposure to sunlight and avoid skin irritants

Exclusion Criteria:

  • Pregnancy, breast feeding
  • Severe excoriations on the hands
  • Need for systemic treatment for atopic dermatitis
  • Known sensitivity to Zarzenda and/or to extract of nut butyrospermum parkii (shea)
  • Known immune deficiency
  • Concomitant infection on hands
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00488241
1401663
No
Not Provided
Not Provided
Bayer
Bayer
Not Provided
Study Director: Bayer Study Director Bayer
Bayer
February 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP